As of close of business last night, Viracta Therapeutics Inc’s stock clocked out at $0.78, down -32.17% from its previous closing price of $1.15. On the day, 604480 shares were traded.
Ratios:
To gain a deeper understanding of VIRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.43 and its Current Ratio is at 1.43. In the meantime, Its Debt-to-Equity ratio is 1.40 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on February 01, 2022, initiated with a Outperform rating and assigned the stock a target price of $10.
On May 03, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $35.
On April 26, 2021, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $18.SVB Leerink initiated its Outperform rating on April 26, 2021, with a $18 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 27 ’24 when Chevallard Daniel R. sold 3,405 shares for $0.73 per share. The transaction valued at 2,493 led to the insider holds 102,306 shares of the business.
Rothera Mark bought 47,906 shares of VIRX for $23,627 on Dec 01 ’23. The President and CEO now owns 100,000 shares after completing the transaction at $0.49 per share. On Nov 30 ’23, another insider, Rothera Mark, who serves as the President and CEO of the company, bought 52,094 shares for $0.49 each. As a result, the insider paid 25,734 and bolstered with 52,094 shares of the company.
Stock Price History:
Over the past 52 weeks, VIRX has reached a high of $2.38, while it has fallen to a 52-week low of $0.43.
Shares Statistics:
A total of 39.09M shares are outstanding, with a floating share count of 27.49M. Insiders hold about 30.00% of the company’s shares, while institutions hold 24.46% stake in the company.
Earnings Estimates
As of right now, VIRS analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.78, with high estimates of $8.57 and low estimates of $5.24.
EPS for the following year is $Stocks, with Stocks analysts recommending between $Stocks and $Index.
